134 related articles for article (PubMed ID: 22394203)
1. Sorafenib in melanoma.
Mangana J; Levesque MP; Karpova MB; Dummer R
Expert Opin Investig Drugs; 2012 Apr; 21(4):557-68. PubMed ID: 22394203
[TBL] [Abstract][Full Text] [Related]
2. Preclinical and clinical development of the oral multikinase inhibitor sorafenib in cancer treatment.
Strumberg D
Drugs Today (Barc); 2005 Dec; 41(12):773-84. PubMed ID: 16474853
[TBL] [Abstract][Full Text] [Related]
3. Protein kinase inhibitors in the treatment of renal cell carcinoma: sorafenib.
Bracarda S; Caserta C; Sordini L; Rossi M; Hamzay A; Crinò L
Ann Oncol; 2007 Jun; 18 Suppl 6():vi22-5. PubMed ID: 17591826
[TBL] [Abstract][Full Text] [Related]
4. Sorafenib.
Hasskarl J
Recent Results Cancer Res; 2010; 184():61-70. PubMed ID: 20072831
[TBL] [Abstract][Full Text] [Related]
5. Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis.
Eisen T; Ahmad T; Flaherty KT; Gore M; Kaye S; Marais R; Gibbens I; Hackett S; James M; Schuchter LM; Nathanson KL; Xia C; Simantov R; Schwartz B; Poulin-Costello M; O'Dwyer PJ; Ratain MJ
Br J Cancer; 2006 Sep; 95(5):581-6. PubMed ID: 16880785
[TBL] [Abstract][Full Text] [Related]
6. Sorafenib: scientific rationales for single-agent and combination therapy in clear-cell renal cell carcinoma.
Gollob JA
Clin Genitourin Cancer; 2005 Dec; 4(3):167-74. PubMed ID: 16425993
[TBL] [Abstract][Full Text] [Related]
7. Sorafenib: a clinical and pharmacologic review.
Iyer R; Fetterly G; Lugade A; Thanavala Y
Expert Opin Pharmacother; 2010 Aug; 11(11):1943-55. PubMed ID: 20586710
[TBL] [Abstract][Full Text] [Related]
8. Novel multitargeted anticancer oral therapies: sunitinib and sorafenib as a paradigm.
Sulkes A
Isr Med Assoc J; 2010 Oct; 12(10):628-32. PubMed ID: 21090521
[TBL] [Abstract][Full Text] [Related]
9. Sensitivity toward sorafenib and sunitinib varies between different activating and drug-resistant FLT3-ITD mutations.
Kancha RK; Grundler R; Peschel C; Duyster J
Exp Hematol; 2007 Oct; 35(10):1522-6. PubMed ID: 17889720
[TBL] [Abstract][Full Text] [Related]
10. Targeted therapy for metastatic renal cell carcinoma.
Motzer RJ; Bukowski RM
J Clin Oncol; 2006 Dec; 24(35):5601-8. PubMed ID: 17158546
[TBL] [Abstract][Full Text] [Related]
11. Sunitinib, sorafenib and mTOR inhibitors in renal cancer.
Radulovic S; Bjelogrlic SK
J BUON; 2007 Sep; 12 Suppl 1():S151-62. PubMed ID: 17935273
[TBL] [Abstract][Full Text] [Related]
12. Sorafenib: in advanced renal cancer.
McKeage K; Wagstaff AJ
Drugs; 2007; 67(3):475-83; discussion 484-5. PubMed ID: 17335301
[TBL] [Abstract][Full Text] [Related]
13. BRAF as therapeutic target in melanoma.
Wellbrock C; Hurlstone A
Biochem Pharmacol; 2010 Sep; 80(5):561-7. PubMed ID: 20350535
[TBL] [Abstract][Full Text] [Related]
14. A phase II trial of sorafenib in metastatic melanoma with tissue correlates.
Ott PA; Hamilton A; Min C; Safarzadeh-Amiri S; Goldberg L; Yoon J; Yee H; Buckley M; Christos PJ; Wright JJ; Polsky D; Osman I; Liebes L; Pavlick AC
PLoS One; 2010 Dec; 5(12):e15588. PubMed ID: 21206909
[TBL] [Abstract][Full Text] [Related]
15. Expression of sorafenib targets in melanoma patients treated with carboplatin, paclitaxel and sorafenib.
Jilaveanu L; Zito C; Lee SJ; Nathanson KL; Camp RL; Rimm DL; Flaherty KT; Kluger HM
Clin Cancer Res; 2009 Feb; 15(3):1076-85. PubMed ID: 19188183
[TBL] [Abstract][Full Text] [Related]
16. Sorafenib: in hepatocellular carcinoma.
Simpson D; Keating GM
Drugs; 2008; 68(2):251-8. PubMed ID: 18197728
[TBL] [Abstract][Full Text] [Related]
17. Sorafenib and sunitinib in the treatment of advanced non-small cell lung cancer.
Gridelli C; Maione P; Del Gaizo F; Colantuoni G; Guerriero C; Ferrara C; Nicolella D; Comunale D; De Vita A; Rossi A
Oncologist; 2007 Feb; 12(2):191-200. PubMed ID: 17296815
[TBL] [Abstract][Full Text] [Related]
18. Role of Raf kinase in cancer: therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway.
Gollob JA; Wilhelm S; Carter C; Kelley SL
Semin Oncol; 2006 Aug; 33(4):392-406. PubMed ID: 16890795
[TBL] [Abstract][Full Text] [Related]
19. Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling.
Wilhelm SM; Adnane L; Newell P; Villanueva A; Llovet JM; Lynch M
Mol Cancer Ther; 2008 Oct; 7(10):3129-40. PubMed ID: 18852116
[TBL] [Abstract][Full Text] [Related]
20. The dual PI3K/mTOR inhibitor PI-103 promotes immunosuppression, in vivo tumor growth and increases survival of sorafenib-treated melanoma cells.
López-Fauqued M; Gil R; Grueso J; Hernandez-Losa J; Pujol A; Moliné T; Recio JA
Int J Cancer; 2010 Apr; 126(7):1549-61. PubMed ID: 19810100
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
